KUALA LUMPUR, 26 JANUARY 2021 – Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) through its wholly-owned subsidiary Duopharma (M) Sendirian Berhad (“DMSB”) has confirmed it will procure and supply to Malaysia’s Ministry of Health (“MoH”) the COVID-19 vaccine known as “Sputnik V” developed by the Gamaleya National Research Institute of Epidemiology and Microbiology (“Gamaleya”).
Kuala Lumpur, December 18, 2019 – Duopharma Biotech Berhad (formerly known as CCM Duopharma Biotech Berhad) (“Duopharma Biotech”) today unveiled its new corporate logo and name at an external rebranding launch. The Company obtained shareholders’ approval for the new corporate identity earlier this year. Duopharma Biotech, which is majority owned by Permodalan Nasional Berhad (PNB), is the largest Malaysian pharmaceutical manufacturer and trading company.
KUALA LUMPUR, 12 NOVEMBER 2020 – Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) has posted a solid set of financial results for the third quarter ended 30 September 2020 with profit before tax holding steady at RM18.57 million (2019: RM19.77 million) against revenue of RM133.77 million (2019: RM142.86 million) despite impact of Covid-19 pandemic.
KUALA LUMPUR, 2 NOVEMBER 2020 – This year’s CHAMPS-NASOM Autism Awareness campaign in Malaysia has advanced to a new level as a result of wider industry collaboration, according to the National Autism Society of Malaysia (“NASOM”) and CHAMPS – Mothers’ Choice for Champions, the established child health supplement brand from the Consumer Healthcare (“CHC”) arm of leading pharmaceutical company Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”).
Shah Alam – Home-grown and rapidly evolving pharmaceutical industry player, Duopharma
Biotech Berhad (“Duopharma Biotech” or the “Company”) through its wholly owned subsidiary,
Duopharma HAPI Sdn Bhd will soon embark on manufacturing its second oncology drug at its
first in Malaysia, Highly Potent Active Pharmaceutical Ingredient (HAPI) Plant in Shah Alam,
to help address the paucity of affordable alternatives to treat cancer.
Growing industry collaboration will reinforce CHAMPS-NASOM Autism Awareness Campaign into the future, says Duopharma Biotech Group MD
2020 CHAMPS-NASOM Autism Awareness Campaign, which marks the fourth year of Champs’ support of NASOM’s nation-wide drive to boost public awareness and acceptance of Autism, includes a contribution of RM50,000
Shah Alam, September 15, 2020 – Home-grown and rapidly evolving pharmaceutical industry player, Duopharma Biotech Berhad (“Duopharma Biotech” or the “Company”) through its wholly owned subsidiary, Duopharma HAPI Sdn Bhd will soon embark on manufacturing its second oncology drug at its first in Malaysia, Highly Potent Active Pharmaceutical Ingredient (HAPI) Plant in Shah Alam, to help address the paucity of affordable alternatives to treat cancer.
KUALA LUMPUR, 13 AUGUST 2020 – Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) has posted a creditable set of financial results for the second quarter ended 30 June 2020 with profit before tax climbing to RM19.39 million (2019: RM18.32 million) against revenue of RM143.33 million (2019: RM145.47 million).
Kuala Lumpur, 28th July 2020 – Around 500 top industry players gathered online to participate in a webinar held in conjunction with the World Halal Conference (WHC) 2020 webinar series spotlighting the halal pharmaceutical industry.The webinar, entitled ‘Embracing a Halal Pharmaceutical Eco-System’, was organised by the Halal Development Corporation (HDC) in collaboration with Duopharma Biotech Berhad (Duopharma Biotech), and KPJ Healthcare Berhad (KPJ) hosted by the Ministry of International Trade and Industry (MITI).
PUTRAJAYA, 17 July – VentureTECH today signed and exchanged a tripartite Memorandum of
Understanding (MoU) with Duopharma Biotech Bhd (Duopharma Biotech) and PanGen Biotech
Inc. (PanGen) toward the establishment of Malaysia’s first commercial biosimilar production
facility in a move to position the country as a regional player in the growing biosimilar market,
whilst improving affordability and accessibility to healthcare in the country.
The MoU signing ceremony was graced and witnessed by the Minister of Science, Technology,
and Innovation (MOSTI), YB Khairy Jamaluddin.
PUTRAJAYA, 17 July 2020 – VentureTECH today signed and exchanged a tripartite Memorandum of Understanding (MoU) with Duopharma Biotech Bhd (Duopharma Biotech) and PanGen Biotech Inc. (PanGen) toward the establishment of Malaysia’s first commercial biosimilar production facility in a move to position the country as a regional player in the growing biosimilar market, whilst improving affordability and accessibility to healthcare in the country.
Duopharma Biotech Berhad’s 19th – and first ever fully virtual – AGM reinforces the Group’s dynamic aim of evolving as a pharmaceutical and healthcare leader with significant milestones during its second year as an independent entity
Strong business fundamentals and core values of the Group are fuelling onward progress through the coronavirus crisis, said Duopharma Biotech leadership
Duopharma Biotech Berhad recorded cumulative revenue of RM482.24 million for the first half of FY2026 ended 30 June 2026, which saw the Group’s Profit Before Tax growing 32.1% year-on-year to RM79.71 million, while Profit After Tax rose 32.2% to RM60.59 million, compared to the corresponding period in the preceding year.
Duopharma Biotech Berhad officially launched the Flavettes Merdeka 2026 campaign today, themed ‘Flavettes Setia Menemani Setiap Generasi’ and featuring a multi-prong collaboration with Tourism Malaysia, Watsons Malaysia and Kapten Batik.
Biocon Limited, an innovation-led global biopharmaceutical company, announced that its long-standing partner, Duopharma Biotech Berhad via its wholly-owned subsidiary Duopharma (M) Sendirian Berhad, has secured multiple insulin contracts from the Ministry of Health, Malaysia, valued at over MYR 225 million this year.
Duopharma Biotech Berhad held its 25th Annual General Meeting today, capping a successful FY2025 ended 31 December 2025, that saw the Company growing its revenue by 14.5% to RM931.69 million, from RM813.70 million in FY2024.
Duopharma Biotech Berhad recorded resilient financial performance in the first quarter ended 31 March 2026, delivering a stronger Profit Before Tax (“PBT”) of RM 40.41 million, and Profit After Tax (“PAT”) of RM30.71 million, increasing 19.8% year-on-year, despite Q1FY2026 revenue of RM247.88 million dropping 5.7% compared to RM262.74 million in the same period last year.
Duopharma Biotech Berhad reported a revenue of RM931.69 million for the year ended 31 December 2025, up 14.5% compared to revenue of RM813.70 million in financial year 2024.
